Results 251 to 260 of about 94,345 (348)
Continued Regulatory Actions Affecting the Use of Erythropoiesis-Stimulating Agents
Karen L. Hagerty
openalex +1 more source
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Weizhe Jian +7 more
wiley +1 more source
CERA Detection and Stability in Blood Versus Urine
This study presents comparative data on CERA detection in serum and urine samples, highlighting adverse analytical findings (AAFs) in serum that were undetected in corresponding urine samples. This shift would significantly improve the efficiency and sensitivity of CERA detection in doping control, ensuring more effective doping control programs ...
Olivier Salamin +4 more
wiley +1 more source
Malaria and dyserythropoiesis: a mini review. [PDF]
Liu FF, Li K.
europepmc +1 more source
Role of inflammation, nutritional status and body mass index in the development of resistance to erythropoiesis-stimulating agents (ESAs) in patients under regular hemodialysis [PDF]
Samia El-Shishtawy +4 more
openalex +1 more source
Our results indicate that although high‐dose parenteral iron effectively corrects iron deficiency anemia (IDA), it causes liver dysfunction, immune suppression, systemic iron overload, and altered gut microbiota. ABSTRACT Iron deficiency anemia (IDA) is a common nutritional disorder in mammals, particularly affecting neonates and neonatal piglets ...
Qian Zhang +4 more
wiley +1 more source
Treatment of pure red cell aplasia in a chronic kidney disease patient with roxadustat: A case report. [PDF]
Liu S, Yan B, He Y.
europepmc +1 more source
Progresses in overcoming the limitations of in vitro erythropoiesis using human induced pluripotent stem cells [PDF]
Hyeonwoo Ju +3 more
openalex +1 more source

